tradingkey.logo

Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial

ReutersJun 2, 2025 12:29 PM

- Regeneron Pharmaceuticals Inc REGN.O:

  • INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRM POTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE (GLP-1 RECEPTOR AGONIST)-INDUCED WEIGHT LOSS BY PRESERVING LEAN MASS

  • REGENERON PHARMACEUTICALS INC - 35% OF SEMAGLUTIDE-INDUCED WEIGHT LOSS DUE TO LEAN MASS LOSS

  • REGENERON PHARMACEUTICALS INC - COMBINATION THERAPY SPARES 50%-80% OF LEAN MASS LOST WITH SEMAGLUTIDE

  • REGENERON PHARMACEUTICALS INC - TRIPLET COMBINATION HAD HIGHER DISCONTINUATION RATE DUE TO ADVERSE EVENTS

  • REGENERON PHARMACEUTICALS INC: COMBINATION OF SEMAGLUTIDE WITH TREVOGRUMAB WAS GENERALLY WELL-TOLERATED

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI